BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:iCell Gene Therapeutics readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies iCell Gene Therapeutics's drugs r
 un\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07544160-85@assetmemo.bio
DTSTAMP:20261121T005937Z
DTSTART;VALUE=DATE:20280407
DTEND;VALUE=DATE:20280408
SUMMARY:ICG318: Phase 1/2 readout est. (NCT07544160)
DESCRIPTION:ICG318\, phase 1/2\, Ulcerative Colitis.\nStudy: BCMA-CD19 cCAR
  T for the Treatment of Refractory Inflammatory Bowel Disease (IBD)\nEstim
 ated primary completion: 7 April 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/icg318#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07544160
URL:https://assetmemo.bio/drug/icg318#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07328581-85@assetmemo.bio
DTSTAMP:20261121T005937Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:ICG318: Phase 2 readout est. (NCT07328581)
DESCRIPTION:ICG318\, phase 2\, Systemic Lupus Erythematosus.\nStudy: A Phas
 e IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus Wit
 h or Without Lupus Nephritis\nEstimated primary completion: December 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/icg318#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07328581
URL:https://assetmemo.bio/drug/icg318#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
